amelparib (JPI-289) / Jeil, Oncocross - LARVOL DELTA

Effects of poly (ADP-ribose) polymerase inhibitor treatment on the repair process of ischemic acute kidney injury. (PubMed, Sci Rep) - "JPI-289 treatment at 3 or 6 h after hypoxia facilitated proliferation of hypoxic HK-2 cells, whereas further treatment after 24 h suppressed proliferation. Delayed inhibition of PARP after renal IRI did not facilitate the repair process during the early healing phase but rather may aggravate renal tubular atrophy during the late healing phase in ischemic AKI."

IO biomarker • Journal • Acute Kidney Injury • Cardiovascular • Fibrosis • Immunology • Nephrology • Renal Disease • Reperfusion Injury

Effects of Delayed Treatment With Poly (ADP-Ribose) Polymerase Inhibitor After Ischemia-Reperfusion on Healing Phase of Renal Injury (KIDNEY WEEK 2022) - "JPI-289 treatment of 0.5 and 0.75 mg/mL at 3 or 6 hours after hypoxia facilitated the proliferation of hypoxic HK-2 cells, whereas further treatment after 24 hours suppressed proliferation even with lower dosages. Conclusion Our results suggest that late treatment of PARP inhibitors after renal IRI did not have a beneficial effect on the recovery of ischemic AKI, but rather could have a negative effect on healing."

Cardiovascular • Fibrosis • Immunology • Renal Disease • Reperfusion Injury

Poly (ADP-Ribose) Polymerase Inhibitor Treatment as a Novel Therapy Attenuating Renal Ischemia-Reperfusion Injury. (PubMed, Front Immunol) - "JPI-289 treatment at 0.5 and 0.75 μg/ml facilitated the proliferation of hypoxic HK-2 cells. PARP inhibition with JPI-289 treatment showed favorable effects in ischemic AKI by attenuating intrarenal inflammatory cascade in a murine model and facilitating proliferation of hypoxic HK-2 cells."

Journal • Acute Kidney Injury • Immune Modulation • Immunology • Inflammation • Nephrology • Renal Disease • Reperfusion Injury

[VIRTUAL] Poly (ADP-Ribose) Polymerase Inhibitor Treatment Attenuated Renal Ischemia-Reperfusion Injury (ATC 2020) - "JPI-289 treatment mitigated renal injury by changing intrarenal immunologic micromilieu favorably in a murine ischemic AKI model and restored proliferation of HK-2 cells after hypoxia."

Late-breaking abstract • Acute Kidney Injury • Gene Therapies • Immunology • Ischemic stroke • Nephrology • Renal Disease • Reperfusion Injury • IFNG • IL2 • PARP1

Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke. (PubMed, Mol Neurobiol) - "Neurological functions also improved in the group treated with JPI-289 (2 h) until 28 days after MCAO. Inhibition of PARP-1 has neuroprotective effects (reduction of infarct volume and brain swelling) in both tMCAO and pMCAO models of ischemic stroke."

Journal • Preclinical • Biosimilar • Cardiovascular • Immunology • Reperfusion Injury • Venous Thromboembolism

Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke (clinicaltrials.gov) - P2a; N=110; Recruiting; Sponsor: Jeil Pharmaceutical Co., Ltd.

New P2a trial • Biosimilar • Reperfusion Injury

Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke (clinicaltrials.gov) - P2a; N=110; Recruiting; Sponsor: Jeil Pharmaceutical Co., Ltd.; Trial completion date: Dec 2019 ➔ Dec 2021

Trial completion date

The Effects of PARP Inhibitor Treatment on Early Renal Injury in a Murine Ischemic AKI Model (KIDNEY WEEK 2019) - "Conclusion JPI-289 treatment attenuated early renal injury in a murine ischemic AKI model and facilitated proliferation of hypoxic HK-2 cells. Further studies are needed to identify optimal dosage and administration timing of JPI-289 treatment."

PARP Biomarker • Preclinical

PARP inhibitor treatment attenuated renal injury in a murine ischemic AKI model (KSN 2019) - "JPI-289 treatment showed favorable effects by attenuating renal injury in a murine ischemic AKI model and facilitating proliferation of hypoxic HK-2 cells. Further studies are required to elucidate optimal dosage and treatment timing of JPI-289 treatment."

PARP Biomarker • Preclinical